SCHEMBL25010442

SCHEMBL25010442

CC(C)Sc1oc(-c2ccc(F)cc2)nc1S(=O)(=O)c1ccc(Br)cc1

nearest known ligand 0.77

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.77
TP53 P04637 10/20 0.77
KDM4E B2RXH2 1/20 0.67
HSD17B10 Q99714 4/20 0.65
ALDH1A1 P00352 4/20 0.65
SMN1; SMN2 Q16637 4/20 0.65
POLB P06746 4/20 0.65
ALOX15 P16050 2/20 0.65
MEN1 O00255 1/20 0.65
BLM P54132 1/20 0.65
KMT2A Q03164 1/20 0.65
NPSR1 Q6W5P4 1/20 0.65
TSHR P16473 4/20 0.60
HTT P42858 2/20 0.60
LMNA P02545 1/20 0.60
HPGD P15428 1/20 0.60
PPARG P37231 1/20 0.51
NCOA2 Q15596 1/20 0.51
NCOA1 Q15788 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25010449 0.94 KDM4E (0.74) MAPTTP53KDM4EHSD17B10ALDH1A1
SCHEMBL25009183 0.90 KDM4E (0.68) MAPTTP53KDM4EHSD17B10ALDH1A1
SCHEMBL25010084 0.89 KDM4E (0.67) MAPTTP53KDM4EHSD17B10ALDH1A1
SCHEMBL25009350 0.88 HSD17B10 (0.76) MAPTTP53KDM4EHSD17B10ALDH1A1
SCHEMBL25010067 0.87 TP53 (1.00) MAPTTP53KDM4EHSD17B10ALDH1A1
SCHEMBL25010142 0.84 MAPT (0.77) MAPTTP53KDM4EHSD17B10ALDH1A1
SCHEMBL25009346 0.83 KDM4E (0.68) MAPTTP53KDM4EHSD17B10ALDH1A1
SCHEMBL25009150 0.82 MAPT (0.74) MAPTTP53KDM4EHSD17B10ALDH1A1
SCHEMBL25009574 0.81 TP53 (0.88) MAPTTP53KDM4EHSD17B10ALDH1A1
SCHEMBL25010433 0.80 KDM4E (1.00) MAPTTP53KDM4EHSD17B10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230041576-A1 METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION 2023-02-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230041576-A1 METHODS AND MATERIALS FOR INHIBITING NF-kB ACTIVITY NFKBIA, IKBKB, NFKB2 MAPT 2111/4885TP53 376/4885KDM4E 2556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.